Early Increases in GDF-15 Are Associated With Declines in Cardiac Function With Breast Cancer Therapy
Authors' conclusion
In women receiving anthracycline- and/or trastuzumab-based breast cancer therapy, early increases in GDF-15 were associated with modest declines in left ventricular ejection fraction and worsening of longitudinal strain, without associations with diastolic measures. These findings support mechanistic investigation of GDF-15 in anthracycline-related cardiotoxicity. (Cardiotoxicity of Cancer Therapy [CCT]; NCT01173341).
Study context
- Population
- Women with breast cancer receiving anthracyclines and/or trastuzumab
- Participants
- 366 women
- Outcome
- GDF-15 concentration
Main finding
As reported in the abstract
- Median baseline GDF-15
- 662
- Early-peak GDF-15
- 1,412 pg/mL
- Trajectories differing across regimens
- P = 0.004
Observational data: associations, not effects.
Further findings
| Outcome | Estimate | P value |
|---|---|---|
| Left ventricular ejection fractionSubsequent 1.5 percentage point decline | β −1.5% percentage point (95% CI −2.5 to −0.6) | P = 0.002 |
| Longitudinal strain0.9-unit worsening | β 0.9 unit (95% CI 0.4–1.4) | P = 0.001 |
Diastolic outcomes, incident diastolic dysfunction, incident cancer therapy-related cardiac dysfunction
- GDF-15 was not associated with diastolic outcomes, incident diastolic dysfunction, or incident cancer therapy-related cardiac dysfunction
Original publication
Early Increases in GDF-15 Are Associated With Declines in Cardiac Function With Breast Cancer Therapy. JACC Adv. Published 2 November 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →